Hypermarcas (OTCMKTS:HYPMY – Get Free Report) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $4.10 and traded as high as $4.18. Hypermarcas shares last traded at $4.16, with a volume of 13,910 shares traded.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the stock. Zacks Research raised shares of Hypermarcas to a “hold” rating in a research report on Wednesday, April 29th. Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy”.
View Our Latest Analysis on HYPMY
Hypermarcas Stock Performance
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 14.63% and a net margin of 19.77%. Equities analysts expect that Hypermarcas will post 0.53 earnings per share for the current fiscal year.
Hypermarcas Company Profile
Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.
Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.
Featured Stories
- Five stocks we like better than Hypermarcas
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
